<DOC>
	<DOCNO>NCT02927925</DOCNO>
	<brief_summary>The purpose study assess clinical efficacy safety daratumumab relapse refractory natural killer/T-cell lymphoma ( NKTCL ) .</brief_summary>
	<brief_title>A Study Assess Clinical Efficacy Safety Daratumumab Participants With Relapsed Refractory Natural Killer/T-Cell Lymphoma ( NKTCL ) , Nasal Type</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Documented histologically confirm extranodal natural killer/Tcell lymphoma ( NK/T ) cell lymphoma , nasal type accord World Health Organization ( WHO ) classification pathology report verify Sponsor Failed least 1 line chemotherapy , accord treat physician investigator , candidate receive treatment modality At least 1 measurable site disease Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 2 Received daratumumab antiCD38 therapy previously Previous allogenic stem cell transplant autologous stem cell transplantation within 12 week first administration study drug Clinical symptom central nervous system involvement Known chronic obstructive pulmonary disease , know moderate severe persistent asthma within past 2 year , uncontrolled asthma classification Clinically significant cardiac disease , include : Myocardial infarction within 6 month first study agent administration , unstable uncontrolled disease/condition relate affect cardiac function ( eg , unstable angina , congestive heart failure , New York Heart Association Class IIIIV ) ; Uncontrolled cardiac arrhythmia ( Common Terminology Criteria Adverse Events [ CTCAE ] [ recent version ] Grade 3 high ) clinically significant ECG abnormality ; Screening 12lead ECG show baseline QT interval correct QTc &gt; 470 msec Seropositive human immunodeficiency virus Active infection hepatitis B hepatitis C Abnormal laboratory value accord protocol define parameter screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>